CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: January 31, 2012
Result type: Reports
Project Number: SR0268-000
Product Line: Reimbursement Review

Generic Name: OnabotulinumtoxinA

Brand Name: Botox

Manufacturer: Allergan Inc.

Therapeutic Area: Neurogenic detrusor overactivity

Indications: Neurogenic Detrusor Overactivity

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: July 19, 2012

Recommendation Type: List with clinical criteria and/or conditions